A pioneering gene therapy called zorevunersen shows promise for Dravet syndrome by targeting the underlying genetic cause SCN1A, rather than just managing symptoms.

In a US-UK trial, 81 children and adolescents aged 2 to 18 received varying zorevunersen doses, with seizure reductions ranging from 59% to 91% over about 20 months and notable improvements in daily functioning and quality of life.

Early results indicate the therapy may improve cognitive and behavioral aspects, with many participants reporting quality-of-life gains over a multi-year period and mostly mild side effects.

Phase Three trials are underway to confirm efficacy and safety, with the aim of paving the way for broader clinical adoption.

The findings were published in the New England Journal of Medicine, reinforcing evidence that zorevunersen can address core symptoms and potentially drive broader cognitive and behavioral improvements.

Supporters group, including Dravet Syndrome UK, emphasize the potential for near-normal lives if treatment continues to optimize and scale.

Current treatments often fail to achieve seizure freedom and do not adequately address motor, behavioral, or cognitive impairments associated with Dravet syndrome.

Experts view these results as a potential shift from purely symptomatic management to addressing the genetic root, with implications for other monogenic epilepsies.

International epilepsy researchers welcomed the study as a significant step toward therapies for hard-to-treat genetic epilepsies.

Independent experts and patient advocates describe the results as incredibly promising and potentially life-changing for families affected by Dravet syndrome.

Optimism remains that improved outcomes could substantially alter long-term prognosis and quality of life for patients.

Leading clinicians call the results promising and potentially life-changing for families dealing with Dravet syndrome.